HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer

Christoph Burdelski; Oliver M Ruge; Nathaniel Melling; Christina Koop; Ronald Simon; Stefan Steurer; Guido Sauter; Martina Kluth; Claudia Hube-Magg; Sarah Minner; Corinna Wittmer; Waldemar Wilczak; Andrea Hinsch; Patrick Lebok; Jakob R Izbicki; Hans Heinzer; Markus Graefen; Hartwig Huland; Thorsten Schlomm; Till Krech

doi:10.1016/j.yexmp.2015.03.024

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer

Standard

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. / Burdelski, Christoph; Ruge, Oliver M; Melling, Nathaniel; Koop, Christina; Simon, Ronald ; Steurer, Stefan ; Sauter, Guido ; Kluth, Martina ; Hube-Magg, Claudia ; Minner, Sarah ; Wittmer, Corinna ; Wilczak, Waldemar ; Hinsch, Andrea ; Lebok, Patrick; Izbicki, Jakob R; Heinzer, Hans; Graefen, Markus; Huland, Hartwig; Schlomm, Thorsten; Krech, Till.

In: EXP MOL PATHOL, Vol. 98, No. 3, 18.03.2015, p. 419-426.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Burdelski, C, Ruge, OM, Melling, N, Koop, C, Simon, R , Steurer, S , Sauter, G , Kluth, M , Hube-Magg, C , Minner, S , Wittmer, C , Wilczak, W , Hinsch, A , Lebok, P, Izbicki, JR, Heinzer, H, Graefen, M, Huland, H, Schlomm, T & Krech, T 2015, 'HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer', EXP MOL PATHOL, vol. 98, no. 3, pp. 419-426. https://doi.org/10.1016/j.yexmp.2015.03.024

APA

Burdelski, C., Ruge, O. M., Melling, N., Koop, C., Simon, R., Steurer, S., Sauter, G., Kluth, M., Hube-Magg, C., Minner, S., Wittmer, C., Wilczak, W., Hinsch, A., Lebok, P., Izbicki, J. R., Heinzer, H., Graefen, M., Huland, H., Schlomm, T., & Krech, T. (2015). HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. EXP MOL PATHOL, 98(3), 419-426. https://doi.org/10.1016/j.yexmp.2015.03.024

Vancouver

Burdelski C, Ruge OM, Melling N, Koop C, Simon R , Steurer S et al. HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. EXP MOL PATHOL. 2015 Mar 18;98(3):419-426. https://doi.org/10.1016/j.yexmp.2015.03.024

Bibtex

@article{e12656808bc546c0b7286f1e2211b8e5,

title = "HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer",

abstract = "Histone deacetylases (HDACs) play an important role in tumor development and progression by modifying histone and non-histone proteins. In the current study we analyzed prevalence and prognostic impact of HDAC1 in prostate cancer. HDAC1 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, and molecular subtypes defined by ERG status as well as genomic deletions of 3p, 5q, 6q and PTEN. HDAC1 immunostaining was detectable in 75.4% of 9744 interpretable cancers and considered strong in 15.4%, moderate in 39.4% and weak in 20.7% of cases. High HDAC1 expression was associated with high Gleason grade (p<0.0001), advanced pathological tumor stage (p<0.0001), positive nodal status (p=0.0010), elevated preoperative PSA-level (p=0.0127), early PSA recurrence (p<0.0001) and increased cell proliferation (p<0.0001). Moreover, high-level HDAC1 staining was associated with TMPRSS2:ERG rearrangement and ERG expression in prostate cancers (p<0.0001) and was linked to deletions of PTEN (p<0.0001), 6q (p<0.0001) and 5q (p=0.0028) in ERG-negative cancers. The prognostic impact of HDAC1 was independent of established clinicopathological parameters and was mostly driven by ERG-negative cancers as revealed by subgroup analyses. HDAC1 has strong prognostic impact in prostate cancer and might contribute to the development of a fraction of genetically instable and particularly aggressive prostate cancers. HDAC1 measurement might therefore be of clinical value for risk stratification of prostate cancer and should be further evaluated in this regard.",

author = "Christoph Burdelski and Ruge, {Oliver M} and Nathaniel Melling and Christina Koop and Ronald Simon and Stefan Steurer and Guido Sauter and Martina Kluth and Claudia Hube-Magg and Sarah Minner and Corinna Wittmer and Waldemar Wilczak and Andrea Hinsch and Patrick Lebok and Izbicki, {Jakob R} and Hans Heinzer and Markus Graefen and Hartwig Huland and Thorsten Schlomm and Till Krech",

year = "2015",

month = mar,

day = "18",

doi = "10.1016/j.yexmp.2015.03.024",

language = "English",

volume = "98",

pages = "419--426",

journal = "EXP MOL PATHOL",

issn = "0014-4800",

publisher = "Academic Press Inc.",

number = "3",

}

RIS

TY - JOUR

T1 - HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer

AU - Burdelski, Christoph

AU - Ruge, Oliver M

AU - Melling, Nathaniel

AU - Koop, Christina

AU - Simon, Ronald

AU - Steurer, Stefan

AU - Sauter, Guido

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Minner, Sarah

AU - Wittmer, Corinna

AU - Wilczak, Waldemar

AU - Hinsch, Andrea

AU - Lebok, Patrick

AU - Izbicki, Jakob R

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Huland, Hartwig

AU - Schlomm, Thorsten

AU - Krech, Till

PY - 2015/3/18

Y1 - 2015/3/18

N2 - Histone deacetylases (HDACs) play an important role in tumor development and progression by modifying histone and non-histone proteins. In the current study we analyzed prevalence and prognostic impact of HDAC1 in prostate cancer. HDAC1 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, and molecular subtypes defined by ERG status as well as genomic deletions of 3p, 5q, 6q and PTEN. HDAC1 immunostaining was detectable in 75.4% of 9744 interpretable cancers and considered strong in 15.4%, moderate in 39.4% and weak in 20.7% of cases. High HDAC1 expression was associated with high Gleason grade (p<0.0001), advanced pathological tumor stage (p<0.0001), positive nodal status (p=0.0010), elevated preoperative PSA-level (p=0.0127), early PSA recurrence (p<0.0001) and increased cell proliferation (p<0.0001). Moreover, high-level HDAC1 staining was associated with TMPRSS2:ERG rearrangement and ERG expression in prostate cancers (p<0.0001) and was linked to deletions of PTEN (p<0.0001), 6q (p<0.0001) and 5q (p=0.0028) in ERG-negative cancers. The prognostic impact of HDAC1 was independent of established clinicopathological parameters and was mostly driven by ERG-negative cancers as revealed by subgroup analyses. HDAC1 has strong prognostic impact in prostate cancer and might contribute to the development of a fraction of genetically instable and particularly aggressive prostate cancers. HDAC1 measurement might therefore be of clinical value for risk stratification of prostate cancer and should be further evaluated in this regard.

AB - Histone deacetylases (HDACs) play an important role in tumor development and progression by modifying histone and non-histone proteins. In the current study we analyzed prevalence and prognostic impact of HDAC1 in prostate cancer. HDAC1 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, and molecular subtypes defined by ERG status as well as genomic deletions of 3p, 5q, 6q and PTEN. HDAC1 immunostaining was detectable in 75.4% of 9744 interpretable cancers and considered strong in 15.4%, moderate in 39.4% and weak in 20.7% of cases. High HDAC1 expression was associated with high Gleason grade (p<0.0001), advanced pathological tumor stage (p<0.0001), positive nodal status (p=0.0010), elevated preoperative PSA-level (p=0.0127), early PSA recurrence (p<0.0001) and increased cell proliferation (p<0.0001). Moreover, high-level HDAC1 staining was associated with TMPRSS2:ERG rearrangement and ERG expression in prostate cancers (p<0.0001) and was linked to deletions of PTEN (p<0.0001), 6q (p<0.0001) and 5q (p=0.0028) in ERG-negative cancers. The prognostic impact of HDAC1 was independent of established clinicopathological parameters and was mostly driven by ERG-negative cancers as revealed by subgroup analyses. HDAC1 has strong prognostic impact in prostate cancer and might contribute to the development of a fraction of genetically instable and particularly aggressive prostate cancers. HDAC1 measurement might therefore be of clinical value for risk stratification of prostate cancer and should be further evaluated in this regard.

U2 - 10.1016/j.yexmp.2015.03.024

DO - 10.1016/j.yexmp.2015.03.024

M3 - SCORING: Journal article

C2 - 25794974

VL - 98

SP - 419

EP - 426

JO - EXP MOL PATHOL

JF - EXP MOL PATHOL

SN - 0014-4800

IS - 3

ER -